Mirkovic K, et al. – In this study, it was presumed that the renoprotective effects of Vitamin D receptor activator (VDRA) treatment, with or without renin–angiotensin–aldosterone system (RAAS) blockade, were modulated by sodium intake. Although demonstrating dependency on dietary sodium status, the renoprotective effects of the VDRA paricalcitol were blood pressure independent. To further retard renal function loss in chronic kidney disease (CKD), the combination of RAAS blockade, dietary sodium restriction and VDRA seemed to be a promising intervention.